Preview Mode Links will not work in preview mode

This Week in Cardiology

Jan 12, 2024

GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

I. GLP-1s and Obesity, BaroStim Neo Revisited

FDA Expands Label for CVRx Barostim System in HF

JAMA Cardiology Special Communication – BDP

II. ATTR Cardiomyopathy

ATTRibute-CM NEJM paper

Circulation Review of TTR

ATTR-ACT (Tafadimis)

III. Clopidogrel vs ASA Years After PCI

Long-term Clopidogrel Has Advantages After Coronary Stenting

Stop DAPT Original Trial

STOP DAPT at 5 Years

Network Meta-analysis of P2Y12-I vs ASA

IV. Statin Use

Statin Use Remains Low for At-Risk Patients

Annals of Internal Medicine Observational Study

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD.

Questions or feedback, please contact